Popular on TelAve
- Zoiko Orbit Launches: Seamless Global Travel Connectivity in 200+ Countries, Including Africa - 883
- ScaleFibre Launches SmartRIBBON™ High-Density Optical Fibre Cables - 589
- Autohaus of Boston Launches Luxury Ferrari Winter Storage Experience - 457
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle' - 392
- IQSTEL, Inc. (N A S D A Q: IQST): Accelerating Toward $1 Billion Revenue with Disruptive AI & Fintech Innovations - 363
- Phinge To Offer All Third Party Platforms On Netverse The Ability To Run Instant Deals Automatically To Increase Sales During Slow Parts Of The Day - 324
- Starlink Local Installers offers national Starlink installations! - 312
- Phinge Asked Google AI, How Could Netverse Disrupt Crypto Like Bitcoin? Its Answer Might Shock You - 287
- Copper Mountain Technologies Introduces Affordable New VTR0102 and VTR0302 VNAs - 284
- Phinge Invites Global Social Media Platforms & Major Brands To Join Netverse App-less Verified Platform To Reward & Safeguard Their Users & Customers - 272
Similar on TelAve
- Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular
- David White DDS Advances Implant Dentistry with New Technology Acquisition
- New Frontier Aerospace Appoints Industry Veteran Rich Pournelle as Director of Business Development
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
- The Truth Behind Egypt's Stolen Legacy: Livestream
- Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
- 'ChilCorp – Water' Builds Momentum After Being Named as a Qualified Team in $119M XPRIZE Water Scarcity Global Competition
- MoArk Dental & Implants Introduces Yomi Robotic Technology for Implant Surgery
- University of Central Florida: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
CCHR: Prescription Psychotropics Fuel America's Addiction and Overdose Crisis
TelAve News/10876957
More than 79 million Americans take psychotropics—millions abuse them, risking overdose—yet the $26 billion psychiatric drug industry's role in the failed war on drugs remains downplayed due to widespread misinformation.
LOS ANGELES - TelAve -- By CCHR International
The abuse of prescription psychotropic drugs has become a global public health issue and, according to the mental health industry watchdog Citizens Commission on Human Rights International (CCHR), it is a major factor in the failure of America's war on drugs. More than 79 million Americans are prescribed psychotropics—many of which can cause dependence, respiratory depression, seizures, and fatal outcomes, especially when combined with other substances.[1] Since 1999, drug overdoses have killed more than one million people in the U.S. In 2021 alone, 32,537 overdose deaths involved stimulants such as cocaine or prescription psychostimulants—a staggering 5,848% increase from 547 deaths in 1999.[2]
Prescription Abuse Epidemic
The National Center for Drug Abuse Statistics reports that 5.9 million Americans abuse sedatives, 4.9 million abuse stimulants, and 4.8 million abuse benzodiazepines. Two million people—nearly 12% of misusers—are addicted. First-time abusers often start with sedatives or tranquilizers, accounting for more than 32% of initial misuse.[3]
Among stimulant abusers, amphetamine/dextroamphetamine is the most frequently misused (75.8% usage rate), followed by methylphenidate at 24.5%.[4] Both drugs are prescribed for Attention Deficit Hyperactivity Disorder (ADHD)—a behavioral construct, not a medically validated disease, or illness that can be cured by a drug. More than 9.5 million Americans are prescribed ADHD stimulants, including 3.1 million minors.[5]
Adult stimulant prescriptions surged 34% between 2019 and 2022. A JAMA Psychiatry study of 84,000 adults (18–64) found that one in four prescribed stimulants abused them.[6] Today, more than half (51%) of stimulant abusers are aged 26 or older.[7] According to IQVIA data, adults aged 31–40, particularly women, and older adults (41–70) saw the steepest rise in stimulant prescribing between 2012 and 2023.[8]
Psychiatric Prescribing Trends & Abuse
In 2022, psychiatrists, pediatricians, and nurse practitioners continued to be the most common prescribers of stimulants.[9] A Medical Expenditure Panel Survey (2016–2019) showed psychiatrists prescribed 33.5% of psychotropics, while general practitioners, nurse practitioners, and physician assistants combined wrote more than 60%.[10] From 2021 to 2023, stimulant marketing payments to physicians doubled from $1.8 million to $3.6 million. The increases were driven in large part by growth in marketing to psychiatrists (a 250% increase). A recent analysis of industry payment data showed that more than $12 billion in payments were made to physicians from 2013 to 2022.[11] Jan Eastgate, President of CCHR International, says, "IQVIA reports U.S. psychiatric drug sales have reached $25.8 billion—underscoring how prescribing and marketing incentives drive a highly lucrative business."
More on TelAve News
The long-term effects of stimulant abuse include heart attack, stroke, seizures, liver and kidney damage, arrhythmia, coma, and death. Sedatives and tranquilizers also carry high risks, including liver failure, amnesia, nightmares, vision loss, depression, and death.[12]
From 2006 to 2023, SSRI antidepressant use among children and adolescents (ages 3–17) rose from 1.5% to 3.6%. Adult prescribing has steadily increased across four major psychotropic classes.[13] The journal Pharmaceuticals warns of SSRI dependence and withdrawal, affecting 55–65% of users.[14] In 2023, SSRIs were implicated in 64,993 single-substance toxic exposures reported to U.S. poison centers, including 285 major outcomes and three fatalities. Rates of SSRI ingestion mirror rising prescription levels.[15]
Misinformation about addiction risks and the perception that prescription drugs are "safer than street drugs" help drive abuse of them.[16] Sixty-two percent of teenagers admitted to abusing prescriptions because they were easily obtained from parents' medicine cabinets, while 35% said they believed prescriptions were safer than illegal substances.[17] College initiates often misuse stimulants as "study aids," while pre-college initiates abuse them recreationally.[18]
CCHR warns that psychiatric diagnostic expansion—driven by the Diagnostic and Statistical Manual of Mental Disorders (DSM)—inflates disorder rates and fuels prescription demand. It criticizes a system in which psychiatrists with financial ties to the pharmaceutical industry vote on which disorders to include.
As Professors Herb Kutchins and Stuart A. Kirk wrote in Making Us Crazy, "DSM is used to directly affect national health policy and priorities by inflating the proportion of the population that is defined as 'mentally disordered.'"[19] These inflated figures drive mental health budgets and prescribing.
The rise of telehealth and e-prescribing, direct-to-consumer (DTC) marketing strategies and subscription-based models—enabled by DSM-based diagnoses—have fueled a surge of direct-to-consumer platforms aggressively marketing adult ADHD treatment through subscription-based models. Both the Drug Enforcement Administration and the Food and Drug Administration have raised concerns over diversion and misuse from such services.[20]
CCHR, established in 1969 by the Church of Scientology and psychiatrist Prof. Thomas Szasz, says urgent action is needed to end the aggressive marketing of psychotropic drugs and the false perception that prescriptions guarantee safety. It emphasizes that people need to be informed that no medical test can confirm a mental disorder, while recognizing that emotional distress is real and can be severe. The watchdog warns that youth, in particular, must be alerted that these drugs carry grave risks of dependence, abuse, and overdose—even when obtained legally from a doctor or psychiatrist.
More on TelAve News
Sources:
[1] "Prevalence and risk factors for misuse of prescription psychotropic drug in patients with severe mental illness: A systematic review," Actas Esp Psiquiatr. 1 Sept. 2023, pmc.ncbi.nlm.nih.gov/articles/PMC10803847/
[2] www.cchrint.org/2023/03/10/cchr-calls-for-more-oversight-after-recent-addiction-treatment-center-closures/
[3] drugabusestatistics.org/prescription-drug-abuse-statistics/
[4] drugabusestatistics.org/prescription-drug-abuse-statistics/
[5] www.cchrint.org/psychiatric-drugs/people-taking-psychiatric-drugs/; www.cchrint.org/psychiatric-drugs/children-on-psychiatric-drugs/
[6] www.webmd.com/add-adhd/news/20250409/america-may-have-a-new-rx-drug-crisis-are-you-part-of-it
[7] drugabusestatistics.org/prescription-drug-abuse-statistics/
[8] "Stimulant Prescription Trends in the United States From 2012-2023," IQVIA Government Solutions, Inc., prepared for the DEA, 13 Nov 2023, pp. 4-5
[9] Ibid.
[10] Psychotropic Medication Prescribing Across Medical Providers, 2016–2019, Psychiatry OnLine, 20 Nov. 2023; www.psychiatryonline.org/doi/10.1176/appi.ps.20230156
[11] www.medpagetoday.com/pediatrics/adhd-add/117138
[12] drugabusestatistics.org/prescription-drug-abuse-statistics/
[13] "U.S. Population Prevalence of Prescription Psychiatric Medication Use Among Children and Adolescents, 2006-2023," ASPE, Office of the Assistant Secretary for Planning and Evaluation, 4 Aug. 2025, aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents
[14] "A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases," Pharmaceuticals, May 2022, pmc.ncbi.nlm.nih.gov/articles/PMC9146999/
[15] "Selective serotonin reuptake inhibitor poisoning," www.uptodate.com/contents/selective-serotonin-reuptake-inhibitor-poisoning
[16] www.ascendhc.com/teen-rehab-blog/prescription-pills-abuse/
[17] drugabusestatistics.org/prescription-drug-abuse-statistics/
[18] drugabusestatistics.org/prescription-drug-abuse-statistics/
[19] Herb Kutchins and Stuart A. Kirk, Making Us Crazy: The Psychiatric Bible and the Creation of Mental Disorders (The Free Press, New York, 1997), p. 243
[20] www.trillianthealth.com/market-research/studies/increases-in-adult-adhd-diagnosis-and-off-label-stimulant-prescribing
The abuse of prescription psychotropic drugs has become a global public health issue and, according to the mental health industry watchdog Citizens Commission on Human Rights International (CCHR), it is a major factor in the failure of America's war on drugs. More than 79 million Americans are prescribed psychotropics—many of which can cause dependence, respiratory depression, seizures, and fatal outcomes, especially when combined with other substances.[1] Since 1999, drug overdoses have killed more than one million people in the U.S. In 2021 alone, 32,537 overdose deaths involved stimulants such as cocaine or prescription psychostimulants—a staggering 5,848% increase from 547 deaths in 1999.[2]
Prescription Abuse Epidemic
The National Center for Drug Abuse Statistics reports that 5.9 million Americans abuse sedatives, 4.9 million abuse stimulants, and 4.8 million abuse benzodiazepines. Two million people—nearly 12% of misusers—are addicted. First-time abusers often start with sedatives or tranquilizers, accounting for more than 32% of initial misuse.[3]
Among stimulant abusers, amphetamine/dextroamphetamine is the most frequently misused (75.8% usage rate), followed by methylphenidate at 24.5%.[4] Both drugs are prescribed for Attention Deficit Hyperactivity Disorder (ADHD)—a behavioral construct, not a medically validated disease, or illness that can be cured by a drug. More than 9.5 million Americans are prescribed ADHD stimulants, including 3.1 million minors.[5]
Adult stimulant prescriptions surged 34% between 2019 and 2022. A JAMA Psychiatry study of 84,000 adults (18–64) found that one in four prescribed stimulants abused them.[6] Today, more than half (51%) of stimulant abusers are aged 26 or older.[7] According to IQVIA data, adults aged 31–40, particularly women, and older adults (41–70) saw the steepest rise in stimulant prescribing between 2012 and 2023.[8]
Psychiatric Prescribing Trends & Abuse
In 2022, psychiatrists, pediatricians, and nurse practitioners continued to be the most common prescribers of stimulants.[9] A Medical Expenditure Panel Survey (2016–2019) showed psychiatrists prescribed 33.5% of psychotropics, while general practitioners, nurse practitioners, and physician assistants combined wrote more than 60%.[10] From 2021 to 2023, stimulant marketing payments to physicians doubled from $1.8 million to $3.6 million. The increases were driven in large part by growth in marketing to psychiatrists (a 250% increase). A recent analysis of industry payment data showed that more than $12 billion in payments were made to physicians from 2013 to 2022.[11] Jan Eastgate, President of CCHR International, says, "IQVIA reports U.S. psychiatric drug sales have reached $25.8 billion—underscoring how prescribing and marketing incentives drive a highly lucrative business."
More on TelAve News
- New Frontier Aerospace Appoints Industry Veteran Rich Pournelle as Director of Business Development
- AI's Urgent Energy Requirements Won't Be Solved By Trillions Of Dollars. Phinge's Patented App-Less Netverse Platform & Hardware Will Reduce This Need
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
- €6.4 Million in Contracts Across Multiple Countries; Smart City Developer; U.S. Expansion, and Announces Strategic Drone Tech Partnership; $AFFU
- CRYPTOCURRENCY: Lucrumia Exchange Platform Addresses Italian Traders' Growing Demand for Secure Digital Asset Trading
The long-term effects of stimulant abuse include heart attack, stroke, seizures, liver and kidney damage, arrhythmia, coma, and death. Sedatives and tranquilizers also carry high risks, including liver failure, amnesia, nightmares, vision loss, depression, and death.[12]
From 2006 to 2023, SSRI antidepressant use among children and adolescents (ages 3–17) rose from 1.5% to 3.6%. Adult prescribing has steadily increased across four major psychotropic classes.[13] The journal Pharmaceuticals warns of SSRI dependence and withdrawal, affecting 55–65% of users.[14] In 2023, SSRIs were implicated in 64,993 single-substance toxic exposures reported to U.S. poison centers, including 285 major outcomes and three fatalities. Rates of SSRI ingestion mirror rising prescription levels.[15]
Misinformation about addiction risks and the perception that prescription drugs are "safer than street drugs" help drive abuse of them.[16] Sixty-two percent of teenagers admitted to abusing prescriptions because they were easily obtained from parents' medicine cabinets, while 35% said they believed prescriptions were safer than illegal substances.[17] College initiates often misuse stimulants as "study aids," while pre-college initiates abuse them recreationally.[18]
CCHR warns that psychiatric diagnostic expansion—driven by the Diagnostic and Statistical Manual of Mental Disorders (DSM)—inflates disorder rates and fuels prescription demand. It criticizes a system in which psychiatrists with financial ties to the pharmaceutical industry vote on which disorders to include.
As Professors Herb Kutchins and Stuart A. Kirk wrote in Making Us Crazy, "DSM is used to directly affect national health policy and priorities by inflating the proportion of the population that is defined as 'mentally disordered.'"[19] These inflated figures drive mental health budgets and prescribing.
The rise of telehealth and e-prescribing, direct-to-consumer (DTC) marketing strategies and subscription-based models—enabled by DSM-based diagnoses—have fueled a surge of direct-to-consumer platforms aggressively marketing adult ADHD treatment through subscription-based models. Both the Drug Enforcement Administration and the Food and Drug Administration have raised concerns over diversion and misuse from such services.[20]
CCHR, established in 1969 by the Church of Scientology and psychiatrist Prof. Thomas Szasz, says urgent action is needed to end the aggressive marketing of psychotropic drugs and the false perception that prescriptions guarantee safety. It emphasizes that people need to be informed that no medical test can confirm a mental disorder, while recognizing that emotional distress is real and can be severe. The watchdog warns that youth, in particular, must be alerted that these drugs carry grave risks of dependence, abuse, and overdose—even when obtained legally from a doctor or psychiatrist.
More on TelAve News
- NIUFO Launches Secure Trading Platform for Italian Market Seeking Stability After 20% User Decline
- OrderDomains.com Empowers Businesses with Premium Domains and Flexible Financing
- Cryptocurrency Trading: AHRFD Enters German Market with Institutional-Grade Infrastructure
- TSWHZC Launches Automated Copy Trading Platform for Brazil's 28 Million Crypto Users
- Keyanb Crypto Exchange Unveils Comprehensive Platform Architecture for Chilean Traders Seeking Lower Fees and Enhanced Security
Sources:
[1] "Prevalence and risk factors for misuse of prescription psychotropic drug in patients with severe mental illness: A systematic review," Actas Esp Psiquiatr. 1 Sept. 2023, pmc.ncbi.nlm.nih.gov/articles/PMC10803847/
[2] www.cchrint.org/2023/03/10/cchr-calls-for-more-oversight-after-recent-addiction-treatment-center-closures/
[3] drugabusestatistics.org/prescription-drug-abuse-statistics/
[4] drugabusestatistics.org/prescription-drug-abuse-statistics/
[5] www.cchrint.org/psychiatric-drugs/people-taking-psychiatric-drugs/; www.cchrint.org/psychiatric-drugs/children-on-psychiatric-drugs/
[6] www.webmd.com/add-adhd/news/20250409/america-may-have-a-new-rx-drug-crisis-are-you-part-of-it
[7] drugabusestatistics.org/prescription-drug-abuse-statistics/
[8] "Stimulant Prescription Trends in the United States From 2012-2023," IQVIA Government Solutions, Inc., prepared for the DEA, 13 Nov 2023, pp. 4-5
[9] Ibid.
[10] Psychotropic Medication Prescribing Across Medical Providers, 2016–2019, Psychiatry OnLine, 20 Nov. 2023; www.psychiatryonline.org/doi/10.1176/appi.ps.20230156
[11] www.medpagetoday.com/pediatrics/adhd-add/117138
[12] drugabusestatistics.org/prescription-drug-abuse-statistics/
[13] "U.S. Population Prevalence of Prescription Psychiatric Medication Use Among Children and Adolescents, 2006-2023," ASPE, Office of the Assistant Secretary for Planning and Evaluation, 4 Aug. 2025, aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents
[14] "A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases," Pharmaceuticals, May 2022, pmc.ncbi.nlm.nih.gov/articles/PMC9146999/
[15] "Selective serotonin reuptake inhibitor poisoning," www.uptodate.com/contents/selective-serotonin-reuptake-inhibitor-poisoning
[16] www.ascendhc.com/teen-rehab-blog/prescription-pills-abuse/
[17] drugabusestatistics.org/prescription-drug-abuse-statistics/
[18] drugabusestatistics.org/prescription-drug-abuse-statistics/
[19] Herb Kutchins and Stuart A. Kirk, Making Us Crazy: The Psychiatric Bible and the Creation of Mental Disorders (The Free Press, New York, 1997), p. 243
[20] www.trillianthealth.com/market-research/studies/increases-in-adult-adhd-diagnosis-and-off-label-stimulant-prescribing
Source: Citizens Commission on Human Rights International
0 Comments
Latest on TelAve News
- The World's No.1 Superstar™ Unveils Fall Lineup With the Re-Release of Holiday Classics
- Building A Business Website That Works In 2025
- The Law Offices of Steinhardt, Siskind and Lieberman, LLC Celebrates 35 Years
- University of Central Florida: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
- LA's Rich & Successful Film Festival Celebrates Sold-Out Fourth Annual Edition
- New Jersey Therapy & Life Coaching Launches "Four Paws, Big Hearts" Fundraiser for Canine Companions
- AGDS Announces ALICE360 ProView EVO™
- Crossroads4Hope to Host Inspiring Hope Gala October 8, 2025
- LEDI Announces 2025 International Life Changers Awards Gala
- Who Will Win the 2025 Video Game of the Year? Bookmakers Review Shares Latest Odds
- International Gaming Platform Launch and Plans to Acquire Racing Women LTD. for AI Powered Sports, Entertainment and Gaming Leader: SEGG Media: $SEGG
- FDA Approval of Suitability Petition on Preservative-Free Ketamine Drug Supports $40 Analyst Target; $3 Billion Suicidal Depression Market: $NRXP
- U.S. Army Orders and Grant Initiative; Key Presentations at Tough Stump Rodeo & Tactical Assault Kit Events for Powerful Video Compression Tech: $RMXI
- Cervey, LLC and PharmaCentra, LLC Announce Strategic Partnership to Expand Pharmacy Technology Support Across Specialty Pharmacy and PBM Services
- Boston Industrial Solutions Introduces Natron® UVPX Series UV-LED Curing Screen Printing Inks
- OddsTrader Releases Latest NBA Finals Odds: Who's the Best Bet to Win in 2026?
- Planetary Constitution Celebrates First Anniversary as Space Policy Shifts Toward Militarization
- DB Landscape Co. Brings Modern Outdoor Living to Coastal Communities
- Alyrica Networks & Rural Prosperity Partners Secure Preliminary BEAD Award for Central Linn SD
- KeysCaribbean Offers 15 Percent Off Luxury Accommodations With Advance Purchase Rate Discount